title: Bisphosphonates, osteonecrosis of the jaw, and dental treatment recommendations.
abstract: Millions of patients in the United States take bisphosphonates for management of malignant bone metastases, osteoporosis, osteitis deformans (Paget's disease), and osteogenesis imperfecta. Since 2003, over 200 cases of osteonecrosis of the jaws have been described, mostly in patients with multiple myeloma or breast cancer patients, and to a lesser extent in patients on oral medications.
authors.affiliation: Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, Oklahoma, USA.
authors.forename: Lida
authors.initials: L
authors.lastname: Radfar
authors.forename: Farah
authors.initials: F
authors.lastname: Masood
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced*; D010020:Osteonecrosis / Q000139:chemically induced*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates